Oral Answers to Questions

Baroness Ritchie of Downpatrick Excerpts

Tuesday 10th May 2016 Commons Chamber

[Ms Margaret Ritchie (South Down) (SDLP)]

Considering the importance and the central role of nurses in the medical profession and in helping people when they are ill, how long does the Minister expect it will take on average for a nurse working in the NHS to pay back the total debt that would be accrued under the Government’s proposed replacement for the bursary scheme?

[Ben Gummer]

It depends of course on the career progression of that particular nurse, but the repayment terms will be precisely those for students of other degrees. Newly qualified nurses will not pay any more than they do currently, and the exact rates at which they will pay back—9% above £21,000—are outlined carefully in the consultation document. I recommend that the hon. Lady looks at it and sees the benefits that will come from the reform that, were it to be adopted in Scotland, would provide an enormous benefit to the service north of the border.

Contaminated Blood

Baroness Ritchie of Downpatrick Excerpts

Tuesday 12th April 2016 Commons Chamber

[Ms Margaret Ritchie (South Down) (SDLP)]

I commend my hon. Friend the Member for Kingston upon Hull North (Diana Johnson) for bringing forward this debate, along with the co-signatories. I was pleased to be one of them.

Today’s debate is the latest in a number of discussions we have held in the Chamber and Westminster Hall on the support arrangements required for people infected with contaminated blood. I pay tribute to the many advocates throughout the UK on the vexatious subject of tainted blood and to the Haemophilia Society. The right hon. Member for North Norfolk (Norman Lamb) said there was striking unanimity across the Chamber that this was not a party political issue but one that impacted on the lives of many people, not only the direct victims but the families, spouses, partners and children who, in many instances, have become carers. It has forced many people into poverty and destitution, which should never have been the case.

There has been a renewed urgency to this debate, particularly since last July’s urgent question, and in that regard I would like to put on the record my thanks to and praise for the work of the all-party group on haemophilia and contaminated blood. However, I would not overstate that urgency, given that publication of the consultation has been repeatedly delayed since its announcement last July and the Prime Minister’s apology on 25 March last year. None the less, I welcome the long-awaited publication of the consultation. I do not necessarily agree with many of the contents, but it is one further step to a full and final settlement for the victims of this tragedy and their families.

Sadly, many have died from their viruses, and for others, every additional day they live is a bonus. This must be dealt with comprehensively once and for all. Let no one be in any doubt: there is no scope for delay. We have spoken at length in previous debates about the impact that the use of contaminated blood products imported back in the 1970s and 1980s has had on people’s lives. Lives have been devastated following the contraction of hepatitis C or HIV as a direct result of these contaminated products.

I have spoken before, in Westminster Hall, about one of my constituents, Brian Carberry, from my local town of Downpatrick. I grew up with him and his family. He and his brothers were born with haemophilia. He received blood transfusions in the 1970s and 1980s, and as a result, his health condition became particularly complicated and he ended up with hepatitis C. Only five or six months ago, he was diagnosed with a rare form of cancer for which he now receives an aggressive form of chemotherapy.

I have also met two other constituents, twin brothers, from South Down, Michael and Seamus Sloane, who have met many difficult health, financial and interpersonal relationship challenges as a result of their haemophilia combined with contaminated blood transfusions. Their lives have been turned upside down. In all our meetings, they asked for a full and final settlement for people like them. It struck me what amazing advocates they were: they took a very sunny approach, they saw a better day ahead. But that better day ahead can be achieved only if the Minister indicates unequivocally that there will be a full and final settlement for people like my constituents and the many others described in this debate.

[Mims Davies (Eastleigh) (Con)]

rose—

[Ms Ritchie]

I am sorry, but I cannot take any interventions because time is limited.

The health problems that thousands face as a result of this tragedy have been exacerbated by the distress and uncertainty around the support arrangements. Irrespective of how bad things have been, I would urge the Minister, having listened to the reasoned demands of Members of all parties, to state clearly that there will be a full and final settlement, that there will be proper transitional arrangements hereafter, and that people so affected will have the right and direct access to the medication required to help them live with their medical conditions, while the families affected by these problems will also be helped. The tragedy of this scandal must be ended and a curtain must be drawn on it.

[Jim Shannon (Strangford) (DUP)]

rose—

Dementia and Alzheimer’s Disease

Baroness Ritchie of Downpatrick Excerpts

Tuesday 12th April 2016 Westminster Hall

[Jim Shannon]

We have to encourage all medical advances.

The number of people living with the condition in the UK is revealed as more startling when we take into account the unsung heroes—the carers.

[Ms Margaret Ritchie (South Down) (SDLP)]

I congratulate the hon. Gentleman on obtaining this debate. He made an important point about the unsung heroes, the carers. Does he agree that often the people who provide the care in the home rely on outside visits, but those are short-term visits, which are not really the answer to support the carer or the person suffering from Alzheimer’s disease or dementia? More work on policy development and resources needs to be invested in by Government in the vital area of caring.

[Jim Shannon]

I thank the hon. Lady for a valuable intervention.

Carers UK estimates that, of the 6.5 million carers in the UK, 670,000 people care for friends or relatives with dementia. It is estimated that the NHS saves some £11.6 billion each year because of those unsung heroes; their contribution as volunteer carers is very valuable. Carers may end up providing more than 100 hours of care per week, and all too often the outside world is completely oblivious to their efforts—even those who know the carers might be oblivious, because they do not know what is happening. Anyone who has lived with someone with dementia or Alzheimer’s, or knows a person who does, knows the problems. People with dementia can often unknowingly become agitated, even violent, and night-time wandering and shouting can have a serious impact on carers’ sleep patterns, let alone sufferers’.

Oral Answers to Questions

Baroness Ritchie of Downpatrick Excerpts

Tuesday 9th February 2016 Commons Chamber

[Jane Ellison]

The challenge of being serious about prevention is one for the entire health and social care system. We acknowledge that, like many parts of government, public health grants have had to absorb some of the fiscal challenge. We are dealing with the problems we inherited at the beginning of the coalition Government. Despite that, local authorities will receive £16 billion in public health grants alone over the spending review period, but that is not the only way we invest in prevention. On my many visits, I have seen some of the great work being done to work with local authorities, and I am confident of the great things they can do with that money.

[Ms Margaret Ritchie (South Down) (SDLP)]

19. Given the report by the Crisp commission, released in the last few days, on mental health provision and treatments, can the Minister provide any assurance about the equitable treatment of physical and mental health to ensure an equal allocation of funds?

[Jane Ellison]

There is rightly a great deal of attention on this area—more tier 4 beds have been commissioned, for example—but I want to stress what is being done in my area of public health. Right at the heart of our new tobacco strategy, which we are beginning to work on, is a concern for the inequity facing people suffering from mental ill health in terms of smoking levels. I can reassure the hon. Lady that across the piece we are considering how we can do more for those who suffer with mental health problems.

Cancer Drugs

Baroness Ritchie of Downpatrick Excerpts

Tuesday 19th January 2016 Westminster Hall

[Ms Margaret Ritchie (South Down) (SDLP)]

It is a pleasure to serve under your chairmanship today, Mr Streeter. I join other hon. Members in congratulating the hon. Member for Mid Derbyshire (Pauline Latham) on securing a debate on a vital issue at such an important time.

No one is unaffected by cancer, and I am sure every Member present will know of a constituent who has had their cancer treatment improved by access to specialist drugs. However, particularly in light of recent decisions, I am sure that we all know stories of constituents and family members who have not had access to the drugs they need, and who have, sadly, suffered as a result. That is why we are here today to discuss this important subject.

There are many who believe that, wherever they live and whatever their age, cancer patients—and there are many different types of cancers—should be able to access clinically effective, evidence-based treatments in a fair, consistent, timely and transparent way from the point of diagnosis. It is therefore deeply regrettable that, given that the Cancer Drugs Fund was already scheduled to come to a close this year, additional funding could not be found to provide the 16 medicines that were delisted last September, at least until a more effective commissioning system for cancer drugs was put in place.

Of course, difficult decisions will always have to be made about the allocation of finite resources, but this has been a particularly hard blow. It is difficult to describe how it must feel for someone to be diagnosed with cancer and then told, as the hon. Member for Mid Derbyshire described, that the life-extending drug they need was funded yesterday but will not be funded today. I take on board the issues about pancreatic cancer, which is one of the severest forms. In fact there are many forms within that spectrum. I note particularly that it was not necessarily resources that were the issue: it was to do with clinical commissioning and clinical effectiveness, and drug trials. Many people who are desperately in need of help and access to drugs, and who feel very unwell, are at the mercy of wider decisions that are part of the NICE agenda and the wider Government agenda.

We may not find ourselves in that position deliberately. However, the Rare Cancers Foundation estimates that it will have been the experience for thousands of patients across Britain and Northern Ireland, and I feel that that suffering should be put on record in our debate today. It is, at the very least, a dire indication of why commissioning reform is needed so badly. It is not too late for the Government to provide the additional support needed to give relief to the patients who are being denied access to life-extending drugs, but, given that such an announcement is unlikely, I shall turn my attention to the ways in which a new system can be designed, to ensure that the same mistake will not happen again.

The funding given for cancer drugs, whether through a Cancer Drugs Fund or a special medicines fund, must be sustainable and well co-ordinated, and should work alongside comprehensive support for treatment and wider health infrastructure. On that basis, the review of how the Cancer Drugs Fund works with NICE should also consider how specialist drug support can be co-ordinated with more localised radiotherapy, chemotherapy and surgery options. Integrating the Cancer Drugs Fund with the NICE system creates an opportunity to address broader issues within the NICE commissioning process, offering the potential remedy for long-standing issues such as access to necessary specialist drugs.

I will mention by way of background, given that I represent a Northern Ireland constituency, a difficulty that we sometimes have. Many specialist drugs are trialled at Queen’s University Belfast, but because of the commissioning process they are not available to our constituents in Northern Ireland. They have not yet been commissioned, or they are commissioned for England and Wales but not necessarily for Northern Ireland. Therefore I urge the UK Ministers responsible for the issue to engage fully with their counterparts in the devolved Administrations, including Northern Ireland, to make sure that the issue is considered fully, and to turn the potential danger into an opportunity to improve both the NHS and access to specialist drugs. I hope that today the Minister, whom I am glad to see here, will provide us with some form of resolution, and a panacea that will bring relief to many people throughout the UK who are suffering from any of a wide variety of cancers, and particularly sufferers of rare cancers.

Victims of Contaminated Blood: Support

Baroness Ritchie of Downpatrick Excerpts

Wednesday 16th December 2015 Commons Chamber

[Jane Ellison]

We aim to consult, and we want to make sure that the final shape of the reformed scheme is informed by that consultation. As I have said, we look to start transitioning to a reformed scheme in the spring. At this stage, however, it is a little difficult to be more precise. We are working hard to ensure that aspects of the transition are being planned and thought about, and this will be informed by the final outcome of the consultation.

[Ms Margaret Ritchie (South Down) (SDLP)]

The Minister wrote to me on 6 November and stated:

“The shape and structure of a new scheme will be decided following the consultation process that will begin by the end of this year as previously committed”—

as it had been committed in an Adjournment debate on 9 September. I am deeply disappointed today that neither that scheme nor that consultation is in place. My constituent, Brian Carberry from Downpatrick in South Down, whom my Adjournment debate was about, has told me in the last few weeks that he now has a form of cancer, with four tumours identified, as a result of the connection with contaminated blood. Will the Minister give me and the House an undertaking today that a full and final settlement will be in place before the end of this financial year.

[Jane Ellison]

I have already made my comments about the timing of the consultation, and I cannot add to what I said in response to the hon. Member for Kingston upon Hull North (Diana Johnson), who put the urgent question. I have often spoken to the hon. Member for South Down (Ms Ritchie) about this and I responded to her Adjournment debate. I think that the language she uses is applicable to circumstances before this exchange. I have already explained the issue of compensation and the principles that we shall try to apply to the reformed scheme. I cannot really add to the comments I made in my response to the hon. Member for Kingston upon Hull North.

Specialist Neuromuscular Care and Treatments

Baroness Ritchie of Downpatrick Excerpts

Tuesday 15th December 2015 Westminster Hall

[Ms Margaret Ritchie (South Down) (SDLP)]

It is a pleasure to serve under your chairmanship, Mr Brady. I congratulate the right hon. Member for Chesham and Amersham (Mrs Gillan) on securing this debate on a vital issue that affects many young people throughout the UK.

As the right hon. Lady said, neuromuscular diseases come in many different forms. In fact, there are about 60 different types of muscular dystrophy and related neuromuscular conditions, which makes it difficult for the NHS to provide clear-cut statistics on the number of people affected by such diseases. However, research undertaken by Muscular Dystrophy UK suggests that out of every 1 million of the UK’s population, approximately 1,000 children and adults are affected by such muscle-wasting conditions. On that basis, we can estimate that some 70,000 of our constituents, of whom approximately 2,000 live in Northern Ireland, are affected by those conditions.

Another way of totalling the scale of the issue is to look at the admission rates of those with neuromuscular diseases to accident and emergency departments. Muscular Dystrophy UK undertook work on that issue and found that in Northern Ireland in 2011, 787 people with a neuromuscular condition were admitted to A&E departments requiring emergency treatment, at an estimated cost of £2.2 million. Those figures are broadly in line with the GB average. There were 28,000 emergency admissions in the UK, at a cost of £81 million. Relying on the emergency services to fill the gaps in treatment for people with such conditions robs people of their independence and costs the NHS much more than a well-designed system that helps people to manage their conditions and avoids emergencies.

I am sure everyone in this Chamber is in agreement on this issue and wants the best possible treatment and care to be provided to people living with the effects of this cruel disease. Unfortunately, we are not there yet. There is still much work to do—in particular, on an issue that the right hon. Lady already referred to: Duchenne muscular dystrophy and the need for Translarna to be commissioned by NICE and approved by its guidelines. It is important that that happens, because Translarna is already in use in France, Germany, Italy and Spain. Families in those countries can use it, but families here are waiting for it.

[Will Quince (Colchester) (Con)]

One of my constituents has two sons with Duchenne. Does the hon. Lady agree that it is deeply regrettable that they are considering moving to France and commuting back to work so that their sons have the vital access to those drugs?

[Ms Ritchie]

I thank the hon. Gentleman for his intervention. I agree. His point illustrates that we urgently need a decision from the Minister. I hope the Minister provides us with some welcome information on that issue. It is deeply regrettable that families will go through Christmas not knowing for sure whether the drug will be approved. In the new year, NICE’s decision must not be delayed further. We must end the difficult wait of those families and children.

In Northern Ireland, there has been a commitment for more adult neuromuscular nurse specialists and adult neuromuscular consultants. I share the hope that, when combined with increased care adviser support, the new specialists will begin to improve our currently overstretched services, although there are still valid concerns about how that can be carried out effectively in the context of broader reorganisation and funding scarcity. If we are to achieve the standard of care we all want, much more must be done to co-ordinate better and join up services to ensure patients with muscle-wasting conditions get the help they need efficiently and effectively.

Before I conclude, I want to mention one of my constituents, a lady called Michaela Hollywood, who is wheelchair-bound and was born with spinal muscular atrophy. She was born without ears and is permanently in a wheelchair. She is now 25 years old. She received a Points of Light award, and on Thursday last week she was with the Prime Minister when the Christmas tree lights were turned on in Downing Street. She is on the BBC’s list of the 100 most inspirational women. She received her undergraduate and master’s degrees from Ulster University, and she hopes to go back to do her PhD. She is a lady of immense capacity. She is a campaigner for young people like her with muscle-wasting conditions and, although she spends every day of her life in a wheelchair, she very much enjoys every one of those days because she is a constant campaigner with enormous zeal for life.

Michaela gave evidence to the all-party group on muscular dystrophy in the Northern Ireland Assembly for its report on specialist neuromuscular care. What she said is most important, because it highlights the need for joined-up Government thinking, whether here at Westminster and in the Department for Health or in the devolved Administrations. She said:

“There’s physiotherapy and hydrotherapy, trying just to cover everything. I do receive physiotherapy but it’s a tricky issue because when you’re under 18, with a neuromuscular condition, you have respiratory physio in the community; when you’re over 18 and in the community, with a neuromuscular condition, you’re with disability physios, even though you’re deemed as having a respiratory problem. So that I think is something that is a prime example of the disjointed care that we’re receiving. If we have one specialist multidisciplinary team…that would make things so much easier. If we had a physio that concentrated on neuromuscular diseases but also had experience within respiratory areas, that would make things easier. Also, if we had a cardiologist who pretty much had a good knowledge all round, that would help too.”

Michaela’s words make the case for a joined-up service better than any of us could, so I will end by simply reiterating her appeal for specialist multidisciplinary teams for the treatment of muscular dystrophy to be established. I call on NICE to make its decision on Translarna with the utmost urgency. I hope the Minister will give us some favourable answers to alleviate the distress that is felt by many people throughout the UK.

Oral Answers to Questions

Baroness Ritchie of Downpatrick Excerpts

Tuesday 17th November 2015 Commons Chamber

[Mr Hunt]

My hon. Friend speaks very wisely on this issue. Yes, this is not about making sure that every hospital is providing every service seven days a week. It is about making sure that in an urgent or emergency situation, people can access the care they need and that, for example, high dependency patients are reviewed twice a day, even at the weekends, by consultants. That happens across all specialties in one in 20 of our hospitals, which is why it is so important to get this right.

[Ms Margaret Ritchie (South Down) (SDLP)]

What assessment has the Department made of the impact of reduced accident and emergency hours, and what effect will that have on the implementation of a seven-day work plan?

Cancer Drugs

Baroness Ritchie of Downpatrick Excerpts

Tuesday 20th October 2015 Westminster Hall

[Jim Shannon]

We have hit on an issue that resonates across the whole House. Let us put on the record the fact that there is a goodly representation of other parties today, and those hon. Members are here because they have an interest in the matter. I am pleased to see the Minister in his place. He tells me that I never miss one of his debates, and I do not know whether this is his debate or mine, but we are both here for the same purpose. I am pleased to see the shadow Minister, the hon. Member for Denton and Reddish (Andrew Gwynne), in his place as well.

Survival rates are improving, and that development is great for everyone.

[Ms Margaret Ritchie (South Down) (SDLP)]

I congratulate the hon. Gentleman on securing this debate about cancer, which impacts on almost every family throughout Northern Ireland and Britain. Before we proceed to talk about cancer drugs, does he agree that it is most important that we have proper diagnosis and proper testing? As well as widening access to cancer drugs, does he agree that access to testing such as Oncotype testing for breast cancer, and BRCA1 and BRCA2 testing for ovarian cancer, is important, because they will suggest the right type of cancer drugs to prescribe—and, indeed, indicate whether cancer drugs are required at all? We need the diagnosis and testing, and then we need the right type of drugs.

[Jim Shannon]

I absolutely agree. The hon. Lady mentioned ovarian cancer. Most of us from Northern Ireland will know of Una McCrudden, who passed away earlier this year. She was an energetic person who spoke out on behalf of those with ovarian cancer. She survived six years after she was first diagnosed, and all her latter years were put into that campaign. I know that the hon. Lady knew her as well as the rest of us did.

Great work has been done on ovarian cancer. Only last week, I heard of one of my constituents who had been diagnosed with ovarian cancer and undergone surgery. The operation was successful, and we thank God for that, but many others do not survive. Survival rates are improving, and given that one in two people diagnosed with cancer in the UK survives, we are on the right track. The fact remains, however, that we could and must do so much better.

With innovation in cancer treatments making great strides, it is imperative that we, as representatives of the people the length and breadth of this nation of the United Kingdom of Great Britain and Northern Ireland, campaign to increase the availability of cancer drugs to our constituents. The Minister and I have discussed this many times. Queen’s University in Belfast is one of the leading advocates for innovation in the search for new cancer drugs, and it leads the way in cancer treatment, as it does in many other spheres of life. Today the Chinese President is visiting Parliament, and we have all sorts of other contacts with China, so it is particularly appropriate to highlight the fact that Queen’s University works in partnership with organisations and universities in China to move that work forward.

Cancer knows no creed, colour, race, religion or class. It is an enemy that we have all come together to fight. With that in mind, I hope that we can all come together to give our constituents up and down this nation access to the very best treatment for that common enemy. We are united in our desire to see greater availability of cancer drugs in every postcode area across the United Kingdom.

--- Later in debate ---

[Jim Shannon]

I could not have said it better. That is exactly the issue for many in the House and for those outside who have to deal directly with these issues.

Moves such as the removal of the drugs prevent thousands of cancer sufferers across England and Wales from being able to access the quality treatment they deserve. Thousands of people are disadvantaged, thousands of families are losing out and thousands of normal people are in despair. Today, we need to give them hope, an advantage and life itself.

The Government have said that the manufacturers of drugs recommended for removal from the Cancer Drugs Fund will have an opportunity to reduce their costs. Negotiations are under way. I am keen to hear the Minister’s response on that. I would like confirmation that patients already receiving a drug that will be removed from the Cancer Drugs Fund will continue to be treated with that drug. Clinicians certainly indicate that they consider it appropriate to continue treatment. The patient needs to be assured that the system is such that those who are on the drugs will continue to be. I had written down the point about pancreatic cancer. The hon. and learned Member for North East Hertfordshire (Sir Oliver Heald) is absolutely right. I thank him for his intervention.

We are living in times when we are all being asked to tighten our belts but when it comes to issues like this, we simply cannot put a price on doing what is right. Given the consequences for patients, it is imperative that we act sooner rather than later. A long-term and sustainable system for cancer drugs is essential and, while we build that, we have to keep doing what we can to improve the lives of those suffering right now. That starts today with this debate. The debate has been happening outside the Chamber and today is an opportunity to highlight to issue in the Chamber.

I am particularly looking forward to hearing the Scottish National party spokesperson today because I was talking to the hon. Member for Central Ayrshire (Dr Whitford) last night at a different debate. She was unable to attend today. The Scottish National party, Scotland and its Parliament have led the way in how cancer drugs can be allocated. There are lessons to be learned from Scotland so the SNP’s comments will be particularly pertinent.

We have an opportunity to do what is right. Today we have an opportunity to make a difference and to affect normal, everyday people’s lives in a positive way. We need to seize that opportunity. Let us use this House for what it was designed for—to help the people we represent. Cancer can strike anyone. It is indiscriminate and that is why we should be doing our best to get what is best for our constituents.

With the working group on the Cancer Drugs Fund currently suspended, it is important to remember that each minute we fail to make progress on the issue we are failing a British citizen suffering from cancer. I need not remind the Chamber of the ultimate consequences of patients being denied access to life-extending treatments. The longer we delay consultation on the new system, the more lives we are failing. Having said that, it is important that we consider the outcome and results rather than just the intention of the actions we take. The Cancer Drugs Fund did great work when it started and the intention of the fund was most honourable. However, we all know of the budgetary constraints that made the Cancer Drugs Fund sustainable, which is why we need to have an open and rational discussion about how to progress.

I should have said this at the beginning, but I will do so now: I thank the hon. Member for Scunthorpe (Nic Dakin), who attended the Backbench Business Committee on my behalf on a Monday about two months ago. I was unable to be over here on that Monday but he did it for me so I thank him publicly for that opportunity.

I welcome the fact that the Cancer Drugs Fund will become operational once again from April 2016, as I welcome any provision of care for cancer sufferers, but it is imperative that we develop a long-term solution that commits us to those who depend on cancer drugs for the extension of their life and for their families. Very often—I see this in my constituency office and I know that other Members do—we see the impact on the families. There are enormous financial, emotional and physical pressures.

[Ms Ritchie]

Is the hon. Gentleman aware that the UK National Screening Committee, which advises the devolved Administrations and the NHS in England on clinical trials, started a process of clinical trials last year? At the debate that I had in this Chamber on 4 November last year, I was told by another Minister in the Department of Health that that evidence base would be assessed for future treatment and diagnostic purposes. Does the hon. Gentleman agree that it would be useful if the Minister, in summing up, advised us of the results of those trials, which could then lead to better treatment and decisions on possible cancer drugs?

[Jim Shannon]

The Minister’s staff are taking notes, and hopefully he will be able to respond positively.

During the transition to the new system, cancer sufferers who were not registered with the Cancer Drugs Fund prior to suspension are not able to access the benefits of the CDF, which is deeply concerning. The second round of delisting will see a further 16 drugs delisted. As the CDF is suspended, patients who did manage to get registered are losing out on drugs that could potentially have been listed and may have been vital to their treatment, which is of concern to everyone in this House.

This is clearly an emotive issue that goes to the heart of everyone here and our constituents across the United Kingdom of Great Britain and Northern Ireland, which is why so many people are in this Chamber today. I thank each and every Member for their interventions and contributions. I look forward to the contributions to come.

Action is urgently needed, but we also need a sensible, rational and robust exchange on how to deliver this positive initiative in a sustainable manner that allows us to have a positive, long-term impact on those who are suffering. I look forward to the contributions of the shadow Minister, the hon. Member for Denton and Reddish, and particularly the Minister, for whom I have the greatest respect. I look forward to his reply with all the positive answers that we want so much.

Oral Answers to Questions

Baroness Ritchie of Downpatrick Excerpts

Tuesday 13th October 2015 Commons Chamber

[Mr Hunt]

My hon. Friend makes a very important point. We have done extensive analysis, because of our commitment to transform the role of general practice, of the issues. They include too much bureaucracy and form-filling, which means that doctors do not spend enough time with patients, and a sense that successive Governments have not invested in general practice and primary care. That is exactly what we seek to turn around with the “Five Year Forward View”.

[Ms Margaret Ritchie (South Down) (SDLP)]

What discussions have taken place with the devolved Administrations regarding the introduction of the new GP contract, particularly the junior doctor contract, given the exodus of junior doctors to Australia?

[Mr Hunt]

We also have Australian paramedics working in the UK, particularly London, so that traffic goes both ways, but, as the hon. Lady will know, health is a devolved matter, and people follow their own paths. For England, we are determined to eliminate the weekend effect. Every year, there are 11,000 excess deaths as a result of inadequate cover at weekends, and we do not want that to continue.